Related Experiment Video
Updated: Jul 15, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
Disease pathology signatures in a mouse model of Mucopolysaccharidosis type IIIB
Ralitsa Petrova1, Abhijeet R Patil2, Vivian Trinh3
1Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA. ralitsaip@gmail.com.
Abstract:
Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare and devastating childhood-onset lysosomal storage disease caused by complete loss of function of the lysosomal hydrolase α-N-acetylglucosaminidase. The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood. The low prevalence and severity of the disease has necessitated the use of animal models to improve our knowledge of the pathophysiology and for the development of therapeutic treatments. In this study, we took a systematic approach to characterizing a classical mouse model of MPS IIIB. Using a series of histological, biochemical, proteomic and behavioral assays, we tested MPS IIIB mice at two stages: during the pre-symptomatic and early symptomatic phases of disease development, in order to validate previously described phenotypes, explore new mechanisms of disease pathology and uncover biomarkers for MPS IIIB. Along with previous findings, this study helps provide a deeper understanding of the pathology landscape of this rare disease with high unmet medical need and serves as an important resource to the scientific community.
Insights
Mucopolysaccharidosis type IIIB (MPS IIIB), a rare childhood disease, involves heparan sulfate buildup due to a missing enzyme. This study characterized a mouse model to understand disease mechanisms and find biomarkers.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare, severe childhood lysosomal storage disease.
- It results from a deficiency in the enzyme α-N-acetylglucosaminidase, leading to heparan sulfate accumulation.
- This accumulation causes neuroinflammation and severe cognitive impairment, necessitating research into pathophysiology and treatments.
Purpose of the Study:
- To systematically characterize a classical mouse model of MPS IIIB.
- To validate known phenotypes and explore novel disease mechanisms.
- To identify potential biomarkers for MPS IIIB.
Main Methods:
- Utilized histological, biochemical, proteomic, and behavioral assays.
- Examined MPS IIIB mice during pre-symptomatic and early symptomatic disease phases.
- Conducted a systematic characterization of the MPS IIIB mouse model.
Main Results:
- Validated previously described phenotypes in the MPS IIIB mouse model.
- Provided insights into new mechanisms driving MPS IIIB pathology.
- Identified potential biomarkers for MPS IIIB.
Conclusions:
- This study deepens the understanding of MPS IIIB pathology.
- Characterization of the mouse model serves as a resource for future research.
- Findings contribute to the development of therapeutic strategies for this rare disease.

